人类结核病疫苗市场按类型、年龄层、分销管道和地区划分

2025 年全球人类结核病疫苗市场规模估计为 6,810 万美元，预计到 2032 年将达到 1.024 亿美元，2025 年至 2032 年的复合年增长率为 6.0%。

数字。 2025 年人类结核病疫苗市场占有率（按地区划分）

儘管结核病是一种可治疗和预防的疾病，但它仍然是全球十大死亡原因之一。目前，唯一广泛使用的结核病疫苗是卡介苗（BCG）疫苗，其保护作用有限，且仅建议儿童使用。迫切需要开发新的有效疫苗来遏制全球结核病负担。几种候选疫苗目前正在进行针对结核菌生命週期不同阶段的临床试验。一种能够持久预防肺结核疾病和传播的疫苗可能会在消灭这种古老病原体的努力中发挥重要作用。

市场动态

全球人类结核病疫苗市场主要受全球持续存在的结核病负担所推动。 2025年10月29日，根据世界卫生组织的数据，2025年将总合125万人死于结核病。结核病在被感染疾病（COVID-19）取代三年后，可能已重新成为世界最大的单一感染疾病死因。对改善诊断方法和疫苗的需求促使国际卫生组织投入大量资金进行结核病疫苗的研究和开发。目前，已有超过15种候选疫苗处于不同阶段的临床试验。然而，高昂的开发成本和监管障碍仍然是挑战。科学家正在探索 mRNA 平台等新技术，以提高结核病疫苗的有效性、安全性和製造的简易性。由于印度和中国等国结核病发生率高，亚太地区是最大的市场。开发有效的疫苗有可能遏制疾病传播并为负担过重的卫生系统节省大量资金。

研究的主要特点

本报告对全球人类结核病疫苗市场进行了详细分析，并以 2024 年为基准年，给出了预测期（2025-2032 年）的市场规模和年复合成长率（CAGR%）。

它还强调了各个领域的潜在商机，并说明了该市场的有吸引力的投资提案矩阵。

它还提供了对市场驱动因素、限制因素、机会、新产品发布和核准、市场趋势、区域前景以及主要企业采用的竞争策略的重要见解。

全球人类结核病疫苗市场的主要企业是根据公司亮点、产品系列、关键亮点、绩效和策略等参数进行分析的。

研究涉及的主要企业包括葛兰素史克公司 (GSK plc.)、印度血清研究所 (Serum Institute of India Pvt.)。 Ltd.、Valneva SE、Archivel Farma、BIOFABRI（Zendal）、日本 BCG 实验室、CSL Seqirus、GreenSignal Bio Pharma Private Limited (GSBPL)、AJ Vaccines A/S、Taj Pharmaceuticals Ltd.、Merck & Co., Inc.、Bharat BIoTechNderTech。

本报告的见解将使负责人和公司经营团队能够就未来的产品发布、规模扩大、市场扩张和行销策略做出明智的决策。

全球人类结核病疫苗市场报告迎合了该行业的各个相关人员，例如投资者、供应商、产品製造商、经销商、新进业者和金融分析师。

相关人员将透过全球人类结核病疫苗市场分析中使用的各种策略矩阵来做出决策。

目录

第一章 调查目的与前提条件

• 研究目标
• 先决条件
• 简称

第二章 市场展望

• 报告描述
  • 市场定义和范围
• 执行摘要

第三章市场动态、法规与趋势分析

• 市场动态
• 影响分析
• 监管情景
• 产品发布/核准
• PEST分析
• 波特分析
• 併购情景
• 流行病学

4. 人类结核病疫苗市场（按类型），2020 年至 2032 年

• 介绍
• 减毒活疫苗
• 不活化疫苗
• 其他的

5. 人类结核病疫苗市场，依年龄组，2020 年至 2032 年

• 介绍
• 孩子们
• 成人

6. 2020 年至 2032 年按分销管道分類的人类结核病疫苗市场

• 介绍
• 私人的
• 公共

7. 人类结核病疫苗市场，依地区、价值，2020 年至 2032 年

• 介绍
• 北美洲
• 拉丁美洲
• 欧洲
• 亚太地区
• 中东
• 非洲

第八章 竞争格局

• GSK plc.
• Serum Institute of India Pvt. Ltd.
• Valneva SE
• Archivel Farma
• BIOFABRI（Zendal）
• Japan BCG Laboratory
• CSL Seqirus
• GreenSignal Bio Pharma Private Limited（GSBPL）
• AJ Vaccines A/S
• Taj Pharmaceuticals Ltd.
• Merck & Co., Inc.
• Bharat BIoTech
• Moderna, Inc.
• BioNTech SE

第 9 章分析师建议

• 兴衰
• 一致的机会地图

第十章参考文献与调查方法

• 参考
• 调查方法
• 关于出版商

Global Human Tuberculosis Vaccine Market is estimated to be valued at USD 68.1 Mn in 2025 and is expected to reach USD 102.4 Mn by 2032, growing at a compound annual growth rate (CAGR) of 6.0% from 2025 to 2032.

Figure. Human Tuberculosis Vaccine Market Share (%), By Region 2025

Tuberculosis remains one of the top 10 causes of death worldwide, despite being a curable and preventable disease. Currently, the only widely used TB vaccine is the Bacille Calmette-Guerin (BCG) vaccine, which provides limited protection and is only recommended for children. There is an urgent need for new, effective vaccines to control the global TB burden. Several candidate vaccines are in clinical trials, targeting different stages of the Mycobacterium tuberculosis lifecycle. Vaccines that provide lasting protection against pulmonary TB disease and transmission could be a game changer in the effort to eliminate this ancient pathogen.

Market Dynamics:

The global human tuberculosis vaccine market is primarily driven by the persistent burden of TB disease worldwide. On October 29, 2025, according to the WHO, a total of 1.25 million people died from tuberculosis (TB) in 2025. Worldwide, TB has probably returned to being the world's leading cause of death from a single infectious agent, following three years in which it was replaced by coronavirus disease (COVID-19). The need for improved diagnostics and vaccines has spurred heavy investments from global health organizations into TB vaccine R&D. Over 15 vaccine candidates are currently in clinical trials of different phases. However, high development costs and regulatory hurdles pose challenges. Scientists are exploring new technologies like mRNA platforms to improve the efficacy, safety, and ease of manufacture of tuberculosis vaccines. Asia Pacific is the largest market due to high TB prevalence in countries like India and China. Developing an effective vaccine could potentially curb disease transmission and generate substantial savings for overburdened healthcare systems.

Key Features of the Study:

This report provides in-depth analysis of the global human tuberculosis vaccine market, and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2025-2032), considering 2024 as the base year

It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market

This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players

It profiles key players in the global human tuberculosis vaccine market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies

Key companies covered as a part of this study include GSK plc., Serum Institute of India Pvt. Ltd., Valneva SE, Archivel Farma, BIOFABRI (Zendal), Japan BCG Laboratory, CSL Seqirus, GreenSignal Bio Pharma Private Limited (GSBPL), AJ Vaccines A/S, Taj Pharmaceuticals Ltd., Merck & Co., Inc., Bharat Biotech, Moderna, Inc., and BioNTech SE

Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics

The global human tuberculosis vaccine market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts

Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global human tuberculosis vaccine market

Market Segmentation

• By Type Insights (Revenue, USD Mn, 2020 - 2032)
  • Live attenuated vaccine
  • Inactivated
  • Others
• By Age Group Insights (Revenue, USD Mn, 2020 - 2032)
  • Pediatrics
  • Adults
• By Distribution Channel Insights (Revenue, USD Mn, 2020 - 2032)
  • Private
  • Public
• By Regional Insights (Revenue, USD Mn, 2020 - 2032)
  • North America
  • U.S.
  • Canada
  • Latin America
  • Brazil
  • Argentina
  • Mexico
  • Rest of Latin America
  • Europe
  • Germany
  • U.K.
  • Spain
  • France
  • Italy
  • Russia
  • Rest of Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • ASEAN
  • Rest of Asia Pacific
  • Middle East
  • GCC Countries
  • Israel
  • Rest of Middle East
  • Africa
  • South Africa
  • North Africa
  • Central Africa
• Key Players Insights
  • GSK plc.
  • Serum Institute of India Pvt. Ltd.
  • Valneva SE
  • Archivel Farma
  • BIOFABRI (Zendal)
  • Japan BCG Laboratory
  • CSL Seqirus
  • GreenSignal Bio Pharma Private Limited (GSBPL)
  • AJ Vaccines A/S
  • Taj Pharmaceuticals Ltd.
  • Merck & Co., Inc.
  • Bharat Biotech
  • Moderna, Inc.
  • BioNTech SE

Table of Contents

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Human Tuberculosis Vaccine Market, By Type
  • Human Tuberculosis Vaccine Market, By Age Group
  • Human Tuberculosis Vaccine Market, By Distribution Channel
  • Human Tuberculosis Vaccine Market, By Region

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
• Impact Analysis
• Key Highlights
• Regulatory Scenario
• Product Launches/Approvals
• PEST Analysis
• PORTER's Analysis
• Merger and Acquisition Scenario
• Epidemiology

4. Human Tuberculosis Vaccine Market, By Type, 2020-2032, (USD Mn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Live attenuated vaccine
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
• Inactivated
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
• Others
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)

5. Human Tuberculosis Vaccine Market, By Age Group, 2020-2032, (USD Mn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Pediatrics
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
• Adults
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)

6. Human Tuberculosis Vaccine Market, By Distribution Channel, 2020-2032, (USD Mn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021- 2032
  • Segment Trends
• Private
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
• Public
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)

7. Human Tuberculosis Vaccine Market, By Region, 2020 - 2032, Value (USD Mn)

• Introduction
  • Market Share (%) Analysis, 2025,2028 & 2032, Value (USD Mn)
  • Market Y-o-Y Growth Analysis (%), 2021 - 2032, Value (USD Mn)
  • Regional Trends
• North America
  • Introduction
  • Market Size and Forecast, By Type, 2020 - 2032, Value (USD Mn)
  • Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Mn)
  • Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Mn)
  • Market Size and Forecast, By Country, 2020 - 2032, Value (USD Mn)
    • U.S.
    • Canada
• Latin America
  • Introduction
  • Market Size and Forecast, By Type, 2020 - 2032, Value (USD Mn)
  • Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Mn)
  • Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Mn)
  • Market Size and Forecast, By Country, 2020 - 2032, Value (USD Mn)
    • Brazil
    • Argentina
    • Mexico
    • Rest of Latin America
• Europe
  • Introduction
  • Market Size and Forecast, By Type, 2020 - 2032, Value (USD Mn)
  • Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Mn)
  • Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Mn)
  • Market Size and Forecast, By Country, 2020 - 2032, Value (USD Mn)
    • Germany
    • U.K.
    • Spain
    • France
    • Italy
    • Russia
    • Rest of Europe
• Asia Pacific
  • Introduction
  • Market Size and Forecast, By Type, 2020 - 2032, Value (USD Mn)
  • Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Mn)
  • Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Mn)
  • Market Size and Forecast, By Country, 2020 - 2032, Value (USD Mn)
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
• Middle East
  • Introduction
  • Market Size and Forecast, By Type, 2020 - 2032, Value (USD Mn)
  • Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Mn)
  • Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Mn)
  • Market Size and Forecast, By Country, 2020 - 2032, Value (USD Mn)
    • GCC Countries
    • Israel
    • Rest of Middle East
• Africa
  • Introduction
  • Market Size and Forecast, By Type, 2020 - 2032, Value (USD Mn)
  • Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Mn)
  • Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Mn)
  • Market Size and Forecast, By Country/Region, 2020 - 2032, Value (USD Mn)
    • South Africa
    • North Africa
    • Central Africa

8. Competitive Landscape

• GSK plc.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Serum Institute of India Pvt. Ltd.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Valneva SE
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Archivel Farma
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• BIOFABRI (Zendal)
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Japan BCG Laboratory
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• CSL Seqirus
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• GreenSignal Bio Pharma Private Limited (GSBPL)
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• AJ Vaccines A/S
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Taj Pharmaceuticals Ltd.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Merck & Co., Inc.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Bharat Biotech
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Moderna, Inc.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• BioNTech SE
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies

9. Analyst Recommendations

• Wheel of Fortune
• Analyst View
• Coherent Opportunity Map

10. References and Research Methodology

• References
• Research Methodology
• About us